AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04141501
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of mannitol (100%)
Trial: NCT04786340
Drug: Active: WST-057 4mL (146 mg pirenzepine free base monohydrate) topical solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WST-057
Trial: NCT04786340
Drug: Placebo: WST-057 4mL topical solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02766803
Drug: Simvastatin and micronized trans-resveratrol
RxNorm normalized name: simvastatin and ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04138472
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous fentanyl at 2mcg/kg in 100ml saline over 10 minutes in induction room.
Trial: NCT01989143
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive single intravenous doses of PF-06480605 matching placebo solution in a dose escalation format.
Trial: NCT01989143
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive three subcutaneous doses of PF-06480605 matching placebo solution in a dose escalation format of one dose every 2 weeks (q2wk).
Trial: NCT01989143
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive three intravenous doses of PF-06480605 matching placebo solution in a dose escalation format of one dose every 2 weeks (q2wk).
Trial: NCT02973724
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The concentration of remifentanil was determined by biased-coin up and down design, starting from 1.0 ng/ml (0.4 ng/ml as a step size)
Trial: NCT03356639
Drug: ASP6981
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT03356639
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01416974
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will first receive a single infusion of therapy conditioning with cyclophosphamide.
Trial: NCT01421823
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 weeks local treatment with placebo ointment
Trial: NCT04606394
Drug: Trelegy Ellipta 100/62.5/25Mcg Inh 30D
RxNorm normalized name: TRELEGY ELLIPTA 100/62.5/25MCG INH 30D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of Trelegy in all patients
Trial: NCT04606394
Drug: Ventolin 90Mcg/Actuation Inhalation Aerosol
RxNorm normalized name: Ventolin 90mcg/actuation Inhalation Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 hours after the administration of Trelegy, administer Ventolin in all patients
Trial: NCT00552084
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo supplements will be taken daily for 24 weeks.
Trial: NCT02946918
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients post-thyroidectomy will receive either levothyroxine in tablet form or in gelcaps. Initial dose 1.5-1.8 mcg per kg, orally and daily
Trial: NCT00557011
Drug: NRP104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg, 50 mg or 70 mg capsules taken orally once daily in the morning
Trial: NCT00557011
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule taken once daily in the morning
Trial: NCT04240704
Drug: JBH492
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-CCR7 antibody-drug conjugate (ADC)
Trial: NCT00436475
Drug: Calcium Carbonate 400 mg orally twice daily
RxNorm normalized name: calcium carbonate 400 MG
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium Carbonate 400 mg orally twice daily
Trial: NCT00436475
Drug: Calcium-Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-Placebo
Trial: NCT02065375
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04374981
Drug: Celecoxib 100mg
RxNorm normalized name: CELECOXIB 100MG CAP
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT03277729
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01665950
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The study uses the Sequential Parallel Comparison design (SPCD), with two 4-week phases: n=30 subjects are randomized 1:1 to simvastatin versus placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 for a further 4 weeks. The SPCD will allow us to pool data from both phases to estimate the simvastatin treatment effect. Subjects who respond in phase 1, and all subjects who receive simvastatin in phase 1, continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed. Dosage for simvastatin or matched placebo 20mg daily for 8 weeks.
Trial: NCT01665950
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects (n=15) are randomized to placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 to statin vs placebo for a further 4 weeks. Subjects who respond in phase 1 continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed. Dosage for simvastatin or matched placebo 20mg daily for 8 weeks.
Trial: NCT00976976
Drug: docetaxel, capecitabine, cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel 60 mg/m2 IV (day 1) every 21 days capecitabine 1,875 mg/m2/day PO, divided two (day 1-day14) every 21 days Cisplatin 60 mg/m2 IV (day 1) every 21 days
Trial: NCT01844648
Drug: NH004 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-oral slow dissolving muco-adhesive thin film
Trial: NCT00650247
Drug: Imitrex® Tablets 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg, single dose fed
Trial: NCT02365389
Drug: Conventional MTZ vaginal gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional MTZ vaginal gel (Tricho gel 0.8%, Sedico, Egypt) twice daily for 5 days
Trial: NCT02125786
Drug: ^1^8F-Fluorodeoxyglucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a contrast media that will be given intravenously to aid in tumor visualization.
Trial: NCT02125786
Drug: ^1^1C-methionine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a contrast media that will be given intravenously to aid in tumor visualization.
Trial: NCT01018550
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02216656
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT02216656
Drug: KRN1493
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT02040857
Drug: Aromatase Inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine Therapy
Trial: NCT02881320
Drug: B/F/TAF (Adult Strength)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50/200/25 mg FDC tablets administered orally once daily without regard to food.
Trial: NCT02881320
Drug: B/F/TAF (Low Dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30/120/15 mg FDC tablets administered orally once daily without regard to food.
Trial: NCT02881320
Drug: B/F/TAF (TOS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x B/F/TAF 1.88/7.5/0.94 mg (total daily dose 3.76/15/1.88 mg) FDC tablets administered orally as TOS, twice daily
Trial: NCT01874366
Drug: P11187
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Part I: Step wise dose escalation(10 to 1500 mg, qd, Oral)~* Part II: Step wise dose escalation in multiple dosing (≤ 1500 mg, qd, Oral) for 14 consecutive days.~* Part III: Study drug administered (≤ 1500 mg, qd, Oral) under fasted or fed conditions in two different periods separated by a wash-out interval.
Trial: NCT01515865
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of matching placebo
Trial: NCT01874366
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules will be matching in appearance with the active drug capsules of P11187.~* In Part I, there will be up to 6 cohorts of 8 subjects each in single dose assessment. Two subjects from each cohort will be dosed with placebo~* In Part II, there will be 3 cohorts of 12 subjects each and three subjects from each cohort will be dosed with placebo
Trial: NCT00191542
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00641537
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who received Cladribine 3.5 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive placebo matched to cladribine tablet 0.875 mg/kg orally administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 during the treatment period of 96 weeks.
Trial: NCT00641537
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who received Cladribine 5.25 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive placebo matched to cladribine tablet 0.875 mg/kg orally administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 during the treatment period of 96 weeks.
Trial: NCT03999164
Drug: [18F]DPA-714 Positron Emission Tomography Scan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will undergo a \[18F\]DPA-714 PET scan of the brain 2 weeks and 2 months following moderate to severe traumatic brain injury to quantify neuroinflammation.
Trial: NCT00419848
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cap 100mg- 100mg/daily
Trial: NCT03592667
Drug: Placebo - Cap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One per day before breakfast during 12 weeks.
Trial: NCT00489333
Drug: ProAlgaZyme
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03994302
Drug: Drug inducing antiphospholipid syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs susceptible to induce immune toxicities such as antiphospholipid syndrome
Trial: NCT00876538
Drug: Placebo Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Control 2 capsules once day with the noon meal
Trial: NCT01895270
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will consist of microcrystalline cellulose.
Trial: NCT03391570
Drug: COX-2 inhibitor
RxNorm normalized name: COX-2 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celebrex 200mg/1cap 2 tablets, take medication an hour before surgery
Trial: NCT03391570
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramnos 250mg/1cap 2 tablets, take medication an hour before surgery
Trial: NCT00869856
Drug: HX575 solution for s.c. administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Containing different strengths of epoetin alfa (1 to 10 KIU), s.c. injection, 1x per week (qw) or 1x every two weeks (q2w), injection into abdomen or upper thigh
Trial: NCT00297128
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 825 mg/m2 bid (on each therapy day of first 4 therapy weeks)
Trial: NCT00954057
Drug: LIPO-102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intraorbital injection
Trial: NCT00954057
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intraorbital injection
Trial: NCT00756236
Drug: P-Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9%NaCl dispensed in 60ml \& 5ml syringes
Trial: NCT04565717
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (0.9% NaCl) matching volume of ALN-HSD doses will be administered SC.
Trial: NCT00127998
Drug: artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03386643
Drug: Bifidobacterium animalis subsp. lactis HN019
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The selected patients will receive capsules to be diluted in 15 ml of water containing 6 x 109 CFUs of Bifidobacterium subsp. lactis HN019 for mouthwash twice a day for 4 weeks.
Trial: NCT04427475
Drug: pabolizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 patients with stage IV EGFR / ALK wild-type NSCLC (squamous cell carcinoma patients do not need to be detected) who received anti-PD-1 (pabolizumab) treatment combined with chemotherapy as the first-line treatment were enrolled in the center. Baseline plasma samples were collected before the treatment, and the efficacy was evaluated once every two treatment cycles. At the same time, plasma samples were collected at key nodes until the patient's progress.
Trial: NCT04270409
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AxMP/pre-medication ATC code: N02BE01 Pharmaceutical form: tablet/ampule/capsule; Route of administration: Intravenous (IV) or per os (PO)
Trial: NCT04270409
Drug: Methylprednisolone or equivalent
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AxMP/pre-medication; ATC code: H02AB04; Pharmaceutical form: vial; Route of administration: Intravenous
Trial: NCT02073448
Drug: CD0271
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02073448
Drug: CD1579
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00552253
Drug: Levothyroxin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxin 100 micogram will be administered once daily 1 hour before meal of just after meal for 3 months, and the dose will be titrate to keep serum TSH level between 0.1\~0.3 mU/L. It will be discontinued for 3 months. Then
Trial: NCT03499899
Drug: LAG525
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAG525 was a concentrate for solution for intravenous infusion, came in 100mg vials as a liquid formulation for infusion and was dosed at 400mg every 21 days. For all arms, LAG525 was infused first
Trial: NCT03499899
Drug: PDR001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spartalizumab was a concentrate for solution for intravenous infusion, came in 100mg vials as a liquid formulation for infusion and was dosed at 300mg every 21 days. Spartalizumab was infused after LAG525
Trial: NCT03697603
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, once daily, 14 weeks
Trial: NCT01404754
Drug: Lactose (inactive placebo)
DrugBank: Lactose (DB04465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in an equivalent weight to midomafetamine HCl will be administered in identical appearing capsules during one of two experimental sessions. An equivalent to the initial and supplemental dose will exist.
Trial: NCT00527033
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT03593785
Drug: AZD8233
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized subjects will receive single SC dose of AZD8233 (dose 1, dose 2, dose 3, dose 4 and dose 5) injection.
Trial: NCT04493359
Drug: Renin-angiotensin system inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: switch anti-hypertensive class
Trial: NCT00293410
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01489254
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (daily) for 9 months followed by additional 15 month GTR 20 mg daily treatment period (Part 2)
Trial: NCT02958566
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03063086
Drug: QVM149 150/50/160 μg o.d.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B
Trial: NCT01893281
Drug: Topical Testosterone Solution
RxNorm normalized name: testosterone Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered topically to axillae.
Trial: NCT02958566
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02958566
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02958566
Drug: Hydrocodone-Acetaminophen Tab 5-325 MG
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02958566
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PCA
Trial: NCT00507819
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One placebo capsule will be taken by mouth three times-a-day.
Trial: NCT02218736
Drug: CERC-501
RxNorm normalized name: CERCIS SILIQUASTRUM WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dosing of 10 mg CERC-501 daily for 8 weeks
Trial: NCT02958566
Drug: HYDROCODONE/ACETAMINOPHEN 5 Mg-325 Mg ORAL TABLET
RxNorm normalized name: hydrocodone/acetaminophen 5 mg-325 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breakthrough
Trial: NCT02218736
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral dosing of 10 mg placebo daily for 8 weeks
Trial: NCT00965978
Drug: ONO-5920 / YM529
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00767728
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules (4 capsules) were administered orally QD, in the morning.
Trial: NCT02972424
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo as a prefilled syringe with all inactive ingredients
Trial: NCT00829140
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02387957
Drug: Fovista®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02877511
Drug: BAY987517
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied liberally to the skin (Formulation: Y73-161
Trial: NCT01111123
Drug: Lac-Hydrin lotion (ammonium lactate lotion 12%) ; UItravate ointment (halobetasol propionate ointment 0.05%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid on weekends only group
Trial: NCT01111123
Drug: Lac-Hydrin lotion (ammonium lactate lotion 12%); placebo ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo on weekends only group
Trial: NCT03107884
Drug: Placebo (Bed Rest)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-comparator. The same quantity of non-active tablets will be given at the same time of day as the Metformin treatment group
Trial: NCT03107884
Drug: Placebo (2 week run-in only)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-comparator. The same quantity of non-active tablets will be given at the same time of day as the Metformin 2 week run-in treatment group.
Trial: NCT06613633
Drug: third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib)
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with advanced EGFR-mutated NSCLC who met the inclusion criteria and received third-generation EGFR-TKI (monotherapy or combined with brain radiotherapy)
Trial: NCT00900159
Drug: matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo prior to daytime sleep for 3 days (at home) and 1 day (in lab)
Trial: NCT02438826
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT04437420
Drug: injection of BEP 800
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection of BEP 800
Trial: NCT03831464
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention will consist in IMP treatment during 30 months with half of the patients treated with matched placebo. Tablets of 500mg will be used at a dose of 2x500mg preferably taken during the evening meal.
Trial: NCT03502070
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose (4 capsules) of placebo
Trial: NCT01865708
Drug: Ethanol Lock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol lock, utilizing 74% ethanol, will begin within 24 hours of urinary catheter placement. The lock will be done every 24 hours for 1 hour. The volume that will be instilled depends upon the fill volume of the catheter, which is imprinted by the manufacturer on each catheter. Once the alcohol is in the catheter, the proximal end of the catheter will be clamped for 1 hour. After the 1 hour dwell time, the clamp will be removed and the alcohol in the lumen of the catheter will be flushed out by the patient's own urine output.
Trial: NCT01735201
Drug: AGN-199201 Dose A
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGN-199201 Dose A applied once or twice daily to the face for 28 days.
Trial: NCT00297180
Drug: GW869682
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01735201
Drug: AGN-199201 Vehicle
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGN-199201 Vehicle applied once or twice daily to the face for 28 days.